Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood markers may predict crush syndrome death risk

NCT ID NCT07433127

Knowledge-focused Sponsor: Ataturk University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This study reviewed medical records of 325 adults with crush syndrome in the ICU to see if certain blood-based inflammation scores could predict who would die within 28 days. Researchers compared these scores to standard severity tools. The goal was to learn if a simple blood test could help doctors identify high-risk patients earlier.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

325 people

The number who actually took part.

Started

Jan 2018

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients diagnosed with crush syndrome and admitted to the intensive care unit of Ataturk University Hospital between January 2018 and September 2025.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Diagnosis of crush syndrome based on clinical and laboratory findings * Admission to the intensive care unit (ICU) between January 1, 2018 and September 30, 2025 * Availability of complete blood count parameters within the first 24 hours of ICU admission Exclusion Criteria: * Age \<18 years * Incomplete medical records * Missing laboratory data required for calculation of inflammatory indices * Patients discharged or transferred within 24 hours of ICU admission

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Critical illness are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Critical Illness crush syndrome Rhabdomyolysis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Critical illness Crush syndrome Rhabdomyolysis Systemic inflammatory response

Contacts and locations

Locations

  • Ataturk University Research Hospital

    Erzurum, 20100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.